A Phase I Dose Escalation Study To Determine The Optimal Biological Dose Of BN83495 - An Oral Steroid Sulphatase Inhibitor - In Postmenopausal Women With Oestrogen-Receptor Positive Breast Cancer Whose Disease Progressed After Prior Therapy For Locally Advanced/Metastatic Disease

Trial Profile

A Phase I Dose Escalation Study To Determine The Optimal Biological Dose Of BN83495 - An Oral Steroid Sulphatase Inhibitor - In Postmenopausal Women With Oestrogen-Receptor Positive Breast Cancer Whose Disease Progressed After Prior Therapy For Locally Advanced/Metastatic Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2013

At a glance

  • Drugs Irosustat (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 May 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 15 Dec 2009 Preliminary results were the subject of a poster presented at the 32nd San Antonio Breast Cancer Symposium, according to an Ipsen media release.
    • 15 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top